Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

https://www.thelancet.com/journals/lanonc/home?dgcid=hubspot_email_cfc24_lanonc_2&utm_campaign=cfc24&utm_medium=email&_hsenc=p2ANqtz-9Or3L_OAnsgs8YnqQCtGzSchdC7347Q9eZDLPHMLWqG6R2z2iFcqtIXFfj54oD-IR81xQ8UAfGYvSRm2Kd4lHXaSaRQw&_hsmi=328412334&utm_content=328412334&utm_source=hs_email